Evidence map›Paper›PMID 39536749›Full record

ArticleMolecular cell2024

Acute multi-level response to defective de novo chromatin assembly in S-phase.

Jan Dreyer, Giulia Ricci, Jeroen van den Berg, Vivek Bhardwaj, Janina Funk, Claire Armstrong, Vincent van Batenburg, Chance Sine, Michael A VanInsberghe, Rinskje B Tjeerdsma and 13 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Molecular cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Proteome-widebioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Jan DreyerHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
Giulia RicciHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
Jeroen van den BergHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Vivek BhardwajHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Janina FunkHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
Claire ArmstrongDepartment of Biochemistry, University of Colorado Boulder, Boulder, CO 80303, USA; BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA.
Vincent van BatenburgHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Chance SineDepartment of Biochemistry, University of Colorado Boulder, Boulder, CO 80303, USA; BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA.
Michael A VanInsbergheHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Rinskje B TjeerdsmaDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Richard MarsmanHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
Imke K MandemakerHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
Simone di SanzoMOLEQLAR Analytics GmbH, Rosenheimer Street 141 h, 81671 Munich, Germany.
Juliette CostantiniHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands.
Stefano G ManzoOncode Institute, Utrecht, the Netherlands; Division of Gene Regulation, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Department of Biosciences, Università degli Studi di Milano, Via Celoria 26, 20133 Milan, Italy.
Alva BiranNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen 2200, Denmark.
Claire BurnyMOLEQLAR Analytics GmbH, Rosenheimer Street 141 h, 81671 Munich, Germany.
Marcel A T M van VugtDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Moritz Völker-AlbertMOLEQLAR Analytics GmbH, Rosenheimer Street 141 h, 81671 Munich, Germany.
Anja GrothNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen 2200, Denmark; Biotech Research & Innovation Centre, University of Copenhagen, Copenhagen 2200, Denmark; Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen 2200, Denmark.
Sabrina L SpencerDepartment of Biochemistry, University of Colorado Boulder, Boulder, CO 80303, USA; BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA.
Alexander van OudenaardenHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Francesca MattiroliHubrecht Institute, KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands. Electronic address: f.mattiroli@hubrecht.eu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-term perturbation of de novo chromatin assembly during DNA replication has profound effects on epigenome maintenance and cell fate. The early mechanistic origin of these defects is unknown. Here, we combine acute degradation of chromatin assembly factor 1 (CAF-1), a key player in de novo chromatin assembly, with single-cell genomics, quantitative proteomics, and live microscopy to uncover these initiating mechanisms in human cells. CAF-1 loss immediately slows down DNA replication speed and renders nascent DNA hyper-accessible. A rapid cellular response, distinct from canonical DNA damage signaling, is triggered and lowers histone mRNAs. In turn, histone variants' usage and their modifications are altered, limiting transcriptional fidelity and delaying chromatin maturation within a single S-phase. This multi-level response induces a p53-dependent cell-cycle arrest after mitosis. Our work reveals the immediate consequences of defective de novo chromatin assembly during DNA replication, indicating how at later times the epigenome and cell fate can be altered.

Indexed as

ChromatinChromatin Assembly and DisassemblyDNA ReplicationHistonesS PhaseTumor Suppressor Protein p53Cell Cycle CheckpointsChromatin Assembly Factor-1DNA DamageEpigenesis, GeneticHumansMitosisProteomicsSignal TransductionSingle-Cell AnalysisTranscription FactorsChromatinChromatin Assembly Factor-1CNOT8 protein, humanHistonesTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53cell cyclechromatin assemblyDNA replicationepigenome stabilityhistone chaperoneshistone mRNAPCNASILAC proteomicssingle-cell sequencing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.